Avanafil

Из Википедије, слободне енциклопедије
Avanafil
Avanafil.svg
Avanafil ball-and-stick.png
Klinički podaci
Drugs.com Monografija
Način primene Oralno
Farmakokinetički podaci
Poluvreme eliminacije 5,36 - 10,66 h
Izlučivanje Renalno
Identifikatori
CAS broj 330784-47-9 ДаY
ATC kod None
PubChem CID 9869929
DrugBank DB06237 ДаY
ChemSpider 8045620 ДаY
ChEBI CHEBI:66876 ДаY
ChEMBL CHEMBL1963681 ДаY
Hemijski podaci
Formula C23H26ClN7O3
Molarna masa 483,951

Avanafil je organsko jedinjenje, koje sadrži 23 atoma ugljenika i ima molekulsku masu od 483,951 Da.[1][2][3][4][5]

Sinteza[уреди]

Avanafil se može sintetisati iz benzilaminskih i pirimidinskih derivata:[6]

Avanafil synthesis.png

Osobine[уреди]

Osobina Vrednost
Broj akceptora vodonika 9
Broj donora vodonika 3
Broj rotacionih veza 9
Particioni koeficijent[7] (ALogP) 2,2
Rastvorljivost[8] (logS, log(mol/L)) -4,9
Polarna površina[9] (PSA, Å2) 125,4

Reference[уреди]

  1. Gur S, Sikka SC, Hellstrom WJ: Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. PMID 18491987
  2. Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A: An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 May 16. PMID 23675780
  3. Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K: Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Ther Adv Urol. 2013 Feb;5(1):35-41. doi: 10.1177/1756287212466282. PMID 23372609
  4. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  5. David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  6. Yamada, K.; Matsuki, K.; Omori, K.; Kikkawa, K.; 2004, U.S. Patent 6.797.709
  7. Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  8. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  9. Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura[уреди]

Spoljašnje veze[уреди]